Boston Scientific To Start-Ups: Don’t Call Us, We’ll Call You
This article was originally published in The Gray Sheet
Executive Summary
It is not news that amid the current global financial crisis, individuals and companies alike are tightening their belts. But Boston Scientific CEO Jim Tobin went out of his way in a speech last week to dissuade start-up firms from expecting investment from his company
You may also be interested in...
Financings In Brief
Boston Scientific raises $140 million for debt repayment: Defibrillator and coronary stent maker will sell the bulk of its private investment portfolio to two investor groups for a total of $140 million in pre-tax proceeds, the company announces June 19. The sale is the latest in a series of divestitures of "non-strategic" assets by Boston Scientific over the last year aimed at helping to pay down debt left over from its April 2006 acquisition of Guidant; Boston Scientific had $7.3 billion in long-term debt as of March 31 (1"The Gray Sheet" April 7, 2008, p. 20). Investment firm Saints Capital will pay $100 million for interests owned by Boston Scientific in 54 companies, while private equity firm Paul Capital Partners will acquire a portfolio of venture funds and companies from Boston Scientific for $40 million. The two deals include "the vast majority" of Boston Scientific's private investment portfolio, states CFO Sam Leno
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.